FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2954188380> ?p ?o ?g. }

• W2954188380 endingPage "2021" @default.
• W2954188380 startingPage "2012" @default.
• W2954188380 abstract "// Clelia Madeddu 1 , Paraskevas Kotsonis 2 , Fabrizio Lavra 2 , Giacomo Chiappe 2 , Luca Melis 3 , Ester Mura 4 , Mario Scartozzi 1 and Antonio Macci&#x00F2; 2 1 Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy 2 Department of Gynecologic Oncology, Azienda Ospedaliera Brotzu, Cagliari, Italy 3 Department of Nuclear Medicine, Azienda Ospedaliera Brotzu, Cagliari, Italy 4 Department of Pathology, Azienda Ospedaliera Brotzu, Cagliari, Italy Correspondence to: Antonio Macci&#x00F2;, email: antoniomaccio56@gmail.com Keywords: laparoscopic total pelvic exenteratio; immunotherapy; synchronous cancer; cervical cancer; next-generation sequencing Received: January 21, 2019     Accepted: February 22, 2019     Published: March 12, 2019 ABSTRACT Background: The treatment of patients with multiple synchronous tumors is challenging and complex. The use of next generation sequencing (NGS) may help in identification of germline mutations in genes involved in a common etiology for both tumors thus allowing a common effective therapeutic strategy. Patients and Methods: We describe the unexpected positive results obtained in a young woman with relapsed chemo-resistant stage IVB cervical and synchronous stage IV lung cancer, who underwent an interdisciplinary approach including palliative surgery with laparoscopic total pelvic exenteratio followed by a chemo-immunotherapy protocol with the anti- Programmed Death (PD)-1 antibody nivolumab plus metronomic cyclophosphamide. The treatment choice was based on tumor PD-Ligand 1 assessment and NGS analysis for the identification of potential treatment targets. Outcomes included tumor objective response and patient-centered outcomes (pain, performance status and overall quality of life). Results: Laparoscopic surgery obtained an immediate symptom control and allowed the early start of medical treatment. One month after combined therapy start the patient achieved a significant improvement in performance status, pain, overall Quality of life and after 3 months she resumed working. After 3 and 6 months of treatment we observed an objective dimensional and metabolic response. Currently, after 24 months (and 48 cycles of nivolumab) the patient is continuing to benefit from treatment: she is in complete remission, with good performance status and she is working and leading a self-dependent life. Conclusion: Our study strongly affirms the efficacy of an interdisciplinary approach including surgical and innovative medical strategies based on immunotherapy in patients with advanced chemo-resistant synchronous cervical and lung cancer. The present findings support the use of NGS to drive a targeted rational treatment especially in heavily pre-treated patients." @default.
• W2954188380 created "2019-07-12" @default.
• W2954188380 creator A5008174094 @default.
• W2954188380 creator A5027364160 @default.
• W2954188380 creator A5034035272 @default.
• W2954188380 creator A5036498332 @default.
• W2954188380 creator A5054904775 @default.
• W2954188380 creator A5080262303 @default.
• W2954188380 creator A5090002200 @default.
• W2954188380 creator A5091884159 @default.
• W2954188380 date "2019-03-12" @default.
• W2954188380 modified "2023-09-25" @default.
• W2954188380 title "Next generation sequencing driven successful combined treatment with laparoscopic surgery and immunotherapy for relapsed stage IVB cervical and synchronous stage IV lung cancer" @default.
• W2954188380 cites W1563081817 @default.
• W2954188380 cites W1940241680 @default.
• W2954188380 cites W1983546578 @default.
• W2954188380 cites W1986370046 @default.
• W2954188380 cites W1991306770 @default.
• W2954188380 cites W2019281980 @default.
• W2954188380 cites W2021379322 @default.
• W2954188380 cites W2029321962 @default.
• W2954188380 cites W2048255809 @default.
• W2954188380 cites W2049553585 @default.
• W2954188380 cites W2051978340 @default.
• W2954188380 cites W2075853683 @default.
• W2954188380 cites W2078954242 @default.
• W2954188380 cites W2080425658 @default.
• W2954188380 cites W2099489128 @default.
• W2954188380 cites W2100047707 @default.
• W2954188380 cites W2104347254 @default.
• W2954188380 cites W2108026478 @default.
• W2954188380 cites W2134866009 @default.
• W2954188380 cites W2136559189 @default.
• W2954188380 cites W2153079241 @default.
• W2954188380 cites W2165619445 @default.
• W2954188380 cites W2202115686 @default.
• W2954188380 cites W2299181842 @default.
• W2954188380 cites W2320213787 @default.
• W2954188380 cites W2323356988 @default.
• W2954188380 cites W2340636398 @default.
• W2954188380 cites W2438931692 @default.
• W2954188380 cites W2515397526 @default.
• W2954188380 cites W2559358813 @default.
• W2954188380 cites W2560367415 @default.
• W2954188380 cites W2572174216 @default.
• W2954188380 cites W2587898769 @default.
• W2954188380 cites W2591704778 @default.
• W2954188380 cites W2592144107 @default.
• W2954188380 cites W2610723832 @default.
• W2954188380 cites W2766016099 @default.
• W2954188380 cites W2767612092 @default.
• W2954188380 cites W2790727075 @default.
• W2954188380 cites W2796494201 @default.
• W2954188380 cites W2805026565 @default.
• W2954188380 cites W2808676322 @default.
• W2954188380 cites W4249483966 @default.
• W2954188380 doi "https://doi.org/10.18632/oncotarget.26769" @default.
• W2954188380 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6459345" @default.
• W2954188380 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31007844" @default.
• W2954188380 hasPublicationYear "2019" @default.
• W2954188380 type Work @default.
• W2954188380 sameAs 2954188380 @default.
• W2954188380 citedByCount "3" @default.
• W2954188380 countsByYear W29541883802019 @default.
• W2954188380 countsByYear W29541883802021 @default.
• W2954188380 countsByYear W29541883802022 @default.
• W2954188380 crossrefType "journal-article" @default.
• W2954188380 hasAuthorship W2954188380A5008174094 @default.
• W2954188380 hasAuthorship W2954188380A5027364160 @default.
• W2954188380 hasAuthorship W2954188380A5034035272 @default.
• W2954188380 hasAuthorship W2954188380A5036498332 @default.
• W2954188380 hasAuthorship W2954188380A5054904775 @default.
• W2954188380 hasAuthorship W2954188380A5080262303 @default.
• W2954188380 hasAuthorship W2954188380A5090002200 @default.
• W2954188380 hasAuthorship W2954188380A5091884159 @default.
• W2954188380 hasBestOaLocation W29541883801 @default.
• W2954188380 hasConcept C121608353 @default.
• W2954188380 hasConcept C126322002 @default.
• W2954188380 hasConcept C143998085 @default.
• W2954188380 hasConcept C146357865 @default.
• W2954188380 hasConcept C151730666 @default.
• W2954188380 hasConcept C2776256026 @default.
• W2954188380 hasConcept C2777701055 @default.
• W2954188380 hasConcept C2778220009 @default.
• W2954188380 hasConcept C2780030458 @default.
• W2954188380 hasConcept C29456083 @default.
• W2954188380 hasConcept C71924100 @default.
• W2954188380 hasConcept C86803240 @default.
• W2954188380 hasConceptScore W2954188380C121608353 @default.
• W2954188380 hasConceptScore W2954188380C126322002 @default.
• W2954188380 hasConceptScore W2954188380C143998085 @default.
• W2954188380 hasConceptScore W2954188380C146357865 @default.
• W2954188380 hasConceptScore W2954188380C151730666 @default.
• W2954188380 hasConceptScore W2954188380C2776256026 @default.
• W2954188380 hasConceptScore W2954188380C2777701055 @default.
• W2954188380 hasConceptScore W2954188380C2778220009 @default.
• W2954188380 hasConceptScore W2954188380C2780030458 @default.
• W2954188380 hasConceptScore W2954188380C29456083 @default.

• next